BioAge Labs

BioAge Labs

  • Founded: 2015
  • Location: Richmond, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1b
  • Therapy area: ICU diaphragm atrophy, illness myopathy
  • Drug types: MUS, NEU, OPH, GER
  • Lead product: BGE-105
  • Product link:
  • Funding: $90M Dec 2020; $23M Jan 2019

job board

Short description:

Computational platform that explores a universe of proprietary and public data to identify and target the molecular factors that influence longevity

Drug notes:

Also Clin1 muscle aging in obesity; NLRP3 Clin0 neuroinflammation, RD ocular inflammation; undisclosed RD brain aging

Long description:

BioAge Labs is developing drugs to address aging and age-associated diseases. Aging affects everyone yet is currently not recognised as a disease with effective therapeutics to extend either healthspan or lifespan. BioAge is addressing this problem by building deep molecular profiles of healthy human samples at different ages to create a map of human aging. This involves the use of proteomics, metabolomics and transcriptomics which can then be inputted to their systems biology and AI-driven BioAge platform to identify key drug targets. Targets are then validated using in vivo aging models. BioAge is currently focusing on muscle and immune aging with drugs targeting core longevity pathways.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy